Clinical Trials

• A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/ Refractory Light Chain Amyloidosis
• A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma (AOST2031)
• A Phase 2 Trial of Chemotherapy followed by Response Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (ACNS2021)
• A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (AGCT1531)
• A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG). (ACNS1821)
• A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features (ACNS2031)
• APhase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND #145355) (ACNS1723)
• A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
• A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
• Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
• Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)
• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

• Acute Leukemia
• Study Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
• Study For Patients With Newly Diagnosed Acute Myeloid Leukemia To See If Drugs for Treating Heart Problems May Help To Prevent Heart Problems
• A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (AAML1831)
• Study for Patients with CD 123+ Acute Myeloid Leukemia (AML), Myelofibrosis (MF) or Chronic Myelomonocytic Leukemia (CML)

• Acute Lymphblastic Leukemia
• A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
• A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy (ACCL1931)

• Acute Myeloid Leukemia
• A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease

• Adult Chronic Kidney Disease
• A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)

• Advanced Solid Tumors
• A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients with Advanced Cancer
• Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination with RP-3500 in Patients with Advanced Solid Tumors
• A Phase 1/2 Research Study for Patients with Ovarian Clear Cell Carcinoma or Endometrial Carcinoma or other Advanced Solid Tumors

• Bile Duct Cancer
• A Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

• Bladder Cancer
• Research study for adults at risk, diagnosed with, or being evaluated for cancer
• Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment.

• Brain Cancer
• Seeking Adults with Progressive Meningiomas
• GBM Agile, study for newly diagnoses and recurrent glioblastomas
• Adults with Recurrent Glioblastoma (GBM) are Invited to Participate in a Research Study
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)

• Brain Tumor
• Seeking Adults with Progressive Meningiomas
• GBM Agile, study for newly diagnoses and recurrent glioblastomas
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)
• A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors (ACCL2031)

• BRCA1
• Research study for ovarian cancer patients with BRCA1 mutations to compare two surgical procedures

• Breast Cancer
• The University of Virginia Cancer Center is seeking women age 65+ with early stage breast cancer for a trial investigating the Pre-Operative Window of adjuvant Endocrine therapy to inform Radiation therapy decisions (POWER)
• Patients with metastatic breast cancer are needed for a study to research an investigational drug combination involving an immunotherapy and a cellular therapy.
• A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
• A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
• A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
• A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC).
• A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
• Ph 3 Open-Label Randomized Study to Assess Efficacy/Safety of Camizestrant vs Standard Endocrine Therapy as Adj. Treatment for Patients with ER+/HER2- Early Breast Cancer at+Intermediate-High/High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
• The POWER II Trial: Seeking women ages 65 years or older with early-stage, estrogen receptor positive (ER+) breast cancer.
• A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)
• S2212; Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

• Carinoma
• Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
• Phase 1/1b single arm, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)

• CarT
• A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - EMN28 – EMagine / 68284528MMY3005- CARTITUDE-6

• Cell therapy
• A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible - EMN28 – EMagine / 68284528MMY3005- CARTITUDE-6

• Cervical Cancer
• A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy with or without immunotherapy for the Treatment of Stages IB2-IIB, III and IVA Cervical Cancer
• Research study for adults with gynecological cancer
• A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
• A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
• A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

• Colorectal Cancer
• Testing the use of BRAF-targeted therapy after surgery and usual chemotherapy for BRAF-mutated colon cancer
• Study for Patients Planning to Undergo Abdominal Surgery for Colorectal, Hepatobiliary, or Gynecologic Cancer
• A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation
• Testing the addition of anti-cancer drug, ZEN003694, to the usual chemotherapy treatment, cetuximab plus encorafenib, for colorectal cancer
• An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
• An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas

• Endometrial Cancer
• A Trial of Radiation Therapy for Adult Women with Early Stage Endometrial Cancer
• A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
• NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

• Esophageal Cancer
• Adults with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma invited to be in a research study
• A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
• A022102: Testing the addition of a third chemotherapy drug to the usual combination of two chemotherapy drugs for metastatic gastroesophageal adenocarcinoma

• Fallopian Tube Cancer
• Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor a positive

• Focused Ultrasound Surgery
• Adults with Recurrent Glioblastoma (GBM) are Invited to Participate in a Research Study
• Study Seeking Adult Patients with Advanced Melanoma Who are Receiving Immune Therapy and Who are Planning to Receive Surgery

• Glioblastoma
• GBM Agile, study for newly diagnoses and recurrent glioblastomas
• Adults with Recurrent Glioblastoma (GBM) are Invited to Participate in a Research Study

• Gynecologic Cancer
• Study for Patients Planning to Undergo Abdominal Surgery for Colorectal, Hepatobiliary, or Gynecologic Cancer

• Head and Neck Cancer
• A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/ or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
• RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (KEVLARx)
• A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma
• A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

• Healthy Subject Study
• Healthy Adults and Lung/Liver Cancer Patients are invited to be in a research study.

• Hematologic Malignancies
• Phase II Randomized Trial Assessing Safety and Efficacy of Combination Reduced-dose Post-Transplant Cyclophosphamide, Tacrolimus, MMF, and Ruxolitinib as Graft-versus-Host Disease Prophylaxis in Adults with Hematologic Malignancies undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

• Hemophilia
• Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial

• Incidental Pancreatic Mucinous Neoplasm (IPMN)
• EA2185 Study: Pancreatic Cyst Screening Comparing Two Methods to Follow Patients with Pancreatic Cysts

• Kidney Cancer
• A phase II multicenter study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma that progressed on a PD-1/PD-L1 checkpoint inhibitor
• Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer

• Kidney Disease
• Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer

• Leukemia
• Study Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
• Study for Patients with High Risk Leukemias or Myelodysplastic Syndrome to Start Supportive Care Earlier in the Treatment Regimen
• Study For Patients With Newly Diagnosed Acute Myeloid Leukemia To See If Drugs for Treating Heart Problems May Help To Prevent Heart Problems
• A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
• A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (AAML1831)
• Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
• A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
• Randomized Phase 2 Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes
• Phase I/II Study of DFP-10917 in Combination with Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
• Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
• A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation
• A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
• A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of CC-486 (ORAL-AZA, ONUREG) in Subjects with Moderate or Severe Hepatic Impairment Compared with Normal Hepatic Function in Adult Subjects with Myeloid Malignancies
• A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease
• Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
• MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH
• A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial (MM1YA-S01)
• A measurable residual disease (MRD) focused, phase II study of venetoclax plus chemotherapy for newly diagnosed younger patients with intermediate risk Acute Myeloid Leukemia (AML): A Tier 1 myeloMATCH Clinical Trial
• A Phase I/II Clinical Trial Evaluating CC-486 in Patients with Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)

• Liver Cancer
• Study for Patients Planning to Undergo Abdominal Surgery for Colorectal, Hepatobiliary, or Gynecologic Cancer
• A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination with Atezolizumab plus Bevacizumab Compared with Placebo plus Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated with Systemic Therapy
• Testing the combination of the anticancer drug durvalumab with chemotherapy (gemcitabine and cisplatin) at improving outcomes for high-risk liver cancer
• Healthy Adults and Lung/Liver Cancer Patients are invited to be in a research study.

• Lung Cancer
• Research study for adults at risk, diagnosed with, or being evaluated for cancer
• A Prospective Randomized Study of ramucirumab plus pembrolizumab versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
• A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered NX-019 in Patients with Advanced, EGFR Mutant Cancer
• Real-Time Monitoring and Modeling of Symptoms and Adverse Events in Lung Cancer Patients Receiving Oral Targeted Therapies for Tumors with Actionable Mutations
• Lung Cancer Surgical Trial
• Healthy Adults and Lung/Liver Cancer Patients are invited to be in a research study.
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
• A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 =50%
• A randomized, double-blind phase 2/3 study of Fianlimab (anti-lag 3 antibody), Cemiplimab (anti-pd-1 antibody), and chemotherapy versus cemiplimab and chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression levels.
• A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer
• Phase II study of adagrasib + stereotactic radiosurgery (SRS) for patients with metastatic KRAS G12C-mutated NSCLC with untreated brain metastases (LUN23-618)
• Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
• A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
• A phase II trial of MOnaliZumab in combination with durvAlumab (MEDI4736) plus platinumbased chemotheRapy for first-line Treatment of extensive stage small cell lung cancer (MOZART)
• A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)
• A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
• Tempus Labs, Inc. / “TEMPUS GEMINI NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC
• A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
• A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
• A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy
• A Randomized Phase II trial for those with EGFR-Mutant, MET-Amplified IV or Recurrent Non-Small Cell Lung Cancer
• Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer – PROSPECT LUNG

• Lymphomas
• A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
• A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
• Study for Patients with Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma (CTCL) Comparing an Investigational Combination of Pembrolizumab (Keytruda) with Decitabine and/or Pralatrexate (PTCL 002)
• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
• A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin lymphoma patients 60 years of age and above (cHL 001)
• A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Participants with Relapsed/Refractory Hematologic Malignancies
• A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator’s Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)
• A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3)
• A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas
• Protocol 10601, A phase 1 study of mosunetuzumab with polatuzumab vedotin and lenalidomide (M+Pola+Len) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
• A Phase II trial Evaluating Safety and Efficacy of Epcoritamab with Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma.
• A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
• NORM: Nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab
• S2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
• A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

• Melanoma
• A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA
• Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study
• A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
• Adults with Metastatic Melanoma to a Single Lymph Node Planning to Undergo Surgery are Invited to Participate in a Research Study.
• A Phase 3, multicenter, randomized, open-label, parallel group, treatment to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma
• A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma
• A Randomized Phase 2 Study of ATR inhibition in advanced PD-(L) 1-refractory Merkel cell carcinoma
• Study Seeking Adult Patients with Advanced Melanoma Who are Receiving Immune Therapy and Who are Planning to Receive Surgery
• A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
• A Phase 3 Study of Fixed Dose Combinations of REGN3767 and REGN2810 Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma
• A Phase 3 Research study for patients with previously untreated Advanced Melanoma

• meningioma
• Seeking Adults with Progressive Meningiomas

• Multiple Myeloma
• Patients With Multiple Myeloma (MM) Are Needed For A Research Study Using an Experimental Cellular Therapy
• Study of Cell Transplantation in Medicare Multiple Myeloma Subjects

• Myelodysplastic Syndrome (MDS)
• Study Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
• Study for Patients with High Risk Leukemias or Myelodysplastic Syndrome to Start Supportive Care Earlier in the Treatment Regimen

• myelofibrosis
• Study of Oral TP-3654 in Patients with Myelofibrosis
• Database Study of Cell Transplant in Medicare Myelofibrosis Subjects
• Study for Patients with CD 123+ Acute Myeloid Leukemia (AML), Myelofibrosis (MF) or Chronic Myelomonocytic Leukemia (CML)

• Myeloma
• A Phase 3 Randomized Study Comparing the Study Medication in Combination with Daratumumab SC and Pomalidomide (Tal-DP) or the Study Medication in Combination with Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants with Relapsed or Refractory Multiple Myeloma who have Received at Least 1 Prior Line of Therapy
• A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
• A Phase 3 Randomized Study Comparing Investigational Medicine Combinations and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

• Neuropathic Pain
• Research Study for Adults with Chronic Pain

• Oral Cancer
• RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (KEVLARx)

• Ovarian Cancer
• Patients with ovarian or peritoneal cancers are needed for a study to research a hormonal drug therapy
• A Phase 1/2 Research Study for Patients with Ovarian Clear Cell Carcinoma or Endometrial Carcinoma or other Advanced Solid Tumors
• Research study for ovarian cancer patients with BRCA1 mutations to compare two surgical procedures
• Patients with recurrent platinum-resistant ovarian cancer are needed for a study to research the combination of abemaciclib and olaparib
• A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
• Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor a positive
• Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
• A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors
• NRG-GY036 A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
• A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers

• Pancreatic Cancer
• Adults with Pancreatic Cancer are Invited to Participate in a Research Study
• A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
• PRECEDE - Pancreatic Cancer Early Detection Consortium

• Pancreatic Cysts
• EA2185 Study: Pancreatic Cyst Screening Comparing Two Methods to Follow Patients with Pancreatic Cysts

• Pediatric Cancer: Relapsed and Refractory Langerhans Cell Histiocytosis
• A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

• Pediatric Cancers: Bone Cancer
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

• Pediatric Cancers: Brain Cancer
• Neuroblastoma Biology Studies: A Children's Oncology Group Study

• Pediatric Cancers: Hodgkin's Disease
• A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-Oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma (AHOD2131)

• Pediatric Cancers: Lymphoma
• A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy (ACCL1931)

• Pediatric Cancers: Neuroblastoma
• Neuroblastoma Biology Studies: A Children's Oncology Group Study
• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

• Pediatric Cancers: Sarcomas
• A Group-Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens

• Peripheral T-Cell Lymphoma (PTCL)
• Study for Patients with Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma (CTCL) Comparing an Investigational Combination of Pembrolizumab (Keytruda) with Decitabine and/or Pralatrexate (PTCL 002)
• Study for Patients with Peripheral T-Cell Lymphoma Comparing an Investigational Combination with Standard Treatment

• Peritoneal Cancer
• Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor a positive
• Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab

• Primary Central Nervous System Lymphoma (PCNSL)
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)

• Prostate
• A Phase 2, Randomized, Open-Label, Study of lorigerlimab with docetaxel or docetaxel alone in Participants with Metastatic Castration-Resistant Prostate Cancer
• Research study for adults with Prostate cancer
• Phase 1/2a, Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients with Advanced Prostate Cancer
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
• A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next generation Hormonal Agent (NHA)
• A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
• Research Exercise Study Seeking Adult Patients with Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)
• Treating prostate cancer that has come back after surgery with apalutamide and targeted radiation based on PET imaging
• A phase 1/2 study of Anti-PSMAXCD28 with or without Anti-PD-1 in patients with metastatic castration-resistant prostate cancer and other tumors associated with PSMA expression

• Prostate Cancer
• Research study for adults at risk, diagnosed with, or being evaluated for cancer
• A Phase 2, Randomized, Open-Label, Study of lorigerlimab with docetaxel or docetaxel alone in Participants with Metastatic Castration-Resistant Prostate Cancer
• Research study for adults with recurrent prostate cancer
• Radiation treatment research study for adults with prostate cancer
• Research study for adults with Prostate cancer
• Phase 1/2a, Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients with Advanced Prostate Cancer
• ) A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
• A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next generation Hormonal Agent (NHA)
• A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
• Research Exercise Study Seeking Adult Patients with Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)
• Treating prostate cancer that has come back after surgery with apalutamide and targeted radiation based on PET imaging
• A phase 1/2 study of Anti-PSMAXCD28 with or without Anti-PD-1 in patients with metastatic castration-resistant prostate cancer and other tumors associated with PSMA expression
• A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
• CCTG-PR26: A Randomized Phase III Clinical Trial For The Addition Of Docetaxel To Androgen Receptor Pathway Inhibitors In Patients With Metastatic Castration Sensitive Prostate Cancer And Suboptimal PSA Response (TRIPLE-SWITCH)
• A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients with Metastatic Castration-Resistant Prostate Cancer

• Radiation Therapy
• Research study for adults with recurrent prostate cancer
• Radiation treatment research study for adults with prostate cancer
• Research study for adults with Prostate cancer

• Rectal Cancer
• Research study for adults with Stage II or III Rectal Cancer.
• A022104: Testing the addition of an anti-cancer drug, irinotecan, to the standard chemotherapy treatment (FOLFOX) after long-course radiation therapy for advanced-stage rectal cancers to improve the rate of complete response and long-term rates of organ preservation and continuing response.

• Sarcoma
• An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas
• A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
• Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
• A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
• EA7222: Measuring if Immunotherapy Plus Chemotherapy is better than Chemotherapy Alone for Patients with Aggressive Poorly Differentiated Sarcomas

• Solid Tumors
• The POWER II Trial: Seeking women ages 65 years or older with early-stage, estrogen receptor positive (ER+) breast cancer.
• A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors
• A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
• A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Metastatic Solid Tumors Which Have Progressed Despite Standard Treatments
• Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)
• Molecular Analysis for Combination Therapy Choice
• A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

• Stem Cell Transplant
• Blood Sample Banking For Future Research
• Study of Cell Transplantation in Medicare Multiple Myeloma Subjects
• Database Study of Cell Transplant in Medicare Myelofibrosis Subjects
• A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-hodgkin lymphoma (NHL)
• Study for Patients with CD 123+ Acute Myeloid Leukemia (AML), Myelofibrosis (MF) or Chronic Myelomonocytic Leukemia (CML)
• Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies, and Marrow Toxic Injuries

• Thrombocytopenia
• A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
• A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea

• Transplant
• Safety Study of Cell Transplant with Unlicensed Cord Blood (CB)

• Uterine Cancer
• Research study for adults with gynecological cancer
• A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial for Selinexor in Maintenance Therapy after Systemic Therapy for Patients with P53 wild-type, Advanced or Recurrent Endometrial Carcinoma
• A phase 1/2 study of EG-70 as an intravesical administration to patients with BCG-unresponsive NMIBC and high-risk patients who are BCG naïve or received incomplete BCG treatment

• Vaginal/Vulval Cancer
• Research study for adults with gynecological cancer